Sorafenib vs sunitinib (targeted agent versus targeted agent)
Overall survival (absolute effect size estimates based on survival rate at 24 months) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes overall survival (absolute effect size estimates based on survival… compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
- HR 0.99 [0.74, 1.33]1 study · 365 participantsVery low